Introduction
Bone marrow-derived, CD34 + progenitor cells have been shown to promote the repair of damaged tissues, offering promise for the treatment of hereditary and acquired human diseases (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . These cells differentiate into endothelia, hematopoietic cells, and possibly neurons, fibroblasts, and muscle (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . CD34 + and AC133 + progenitor cells may participate in neovascularization by differentiating into endothelial cells (1) (2) (3) (4) (5) (6) . Neovascularization stimulates healing of injured tissues (1) (2) (3) (4) (5) (6) (7) 14) but also promotes tumor growth and inflammatory disease (14) (15) (16) (17) . Circulating bone marrow-derived progenitor cells home to sites of neovascularization (1) (2) (3) (4) (5) (6) (7) (14) (15) (16) (17) , where they can give rise to approximately 15% of the tumor neovasculature (16) . These cells may thus participate in tissue regeneration or pathogenesis (8) (9) (10) (11) (12) (13) . Although some studies indicate progenitor cells differentiate into a variety of cell types (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , others suggest they may fuse with differentiated hepatocytes or muscle cells, creating the appearance of differentiation (18, 19) . Nevertheless, the evidence that these cells promote tissue repair is strong, although the molecular mechanism(s) that promote the homing and recruitment of bone marrow-derived progenitor cells to remodeling tissues remain unclear.
Integrins and their ligands promote endothelial cell migration and survival during angiogenesis (20) . However, our studies demonstrate that the fibronectin receptor α 4 β 1 plays 2 unique roles during angiogenesis. We recently found that this integrin mediates intercellular adhesion and survival of endothelial cells and pericytes during blood vessel formation in vivo and that this integrin is required for angiogenesis (21) . However, integrin α 4 β 1 is best known as a lymphocyte integrin that mediates adhesion of circulating lymphocytes to VCAM expressed on activated endothelia in inflamed tissues, thereby promoting extravasation of lymphocytes into inflamed tissue (22, 23) . In the studies presented here, we found that integrin α 4 β 1 promotes the homing of circulating bone marrow-derived progenitor cells to the α 4 β 1 ligands, VCAM, and cellular fibronectin, which are expressed on neovasculature. By regulating the homing of these cells, this integrin also promotes their participation in angiogenesis and tumor growth.
Results

CD34 + cells home to the tumor periphery. Bone marrow-derived pro-
genitor cells have been shown to contribute to tumor neovasculature and other tissue repair processes by differentiating into endothelial cells, hematopoietic cells, and other cell types (1) (2) (3) (4) (5) (6) (7) . To understand how progenitor cells as well as other circulating cells home to remodeling tissues, such as the tumor microenvironment, we initially employed real time-intravital microscopy to study the movement of circulating human cells transplanted into mice with breast carcinomas (Figures 1 and 2 ). CD34 + progenitor cells were isolated by magnetic bead affinity selection from human PBMCs; the purified CD34 + comprised approximately 0.1% of the total PBMC population and was 98% pure ( Figure 3A ). CD34 + -positive cells were labeled with a red fluorescent cell tracking dye, 5-and-6-4-chloromethylbenzoylamino-tetramethylrhodamine (CMTMR). One million fluorescent CD34 + cells per mouse were injected into the tail veins of nude mice implanted with murine N202 breast carcinoma spheroids on mammary fat-pads under dorsal skinfold chambers ( Figure 1A ). Intravital microscopy enabled us to track cell homing within tumors and adjacent normal tissue. Tumors ( Figure 1B ) and associated blood vessels ( Figure 1C) were visible in the transparent chambers, permitting analysis of real-time cell movement within the vasculature. Within a few minutes after intravascular injection, human bone marrow-derived CD34 + cells were observed circulating within the tumor vasculature. Approxi-mately 10 minutes after injection, fluorescent cells were observed first rolling, then arresting in blood vessels at the tumor periphery ( Figure 1D ), but not at the tumor center ( Figure 1D ), neighboring breast fat-pad, or uninvolved skin (not shown). Cell homing was not dependent on the density of blood vessels in the tumor tissue, as extensive vascularization was observed in the center and periphery of the tumor ( Figure 1D ). Within 15 minutes after injection, no further fluorescent cells were observed arresting in blood vessels. The arrested cells remained in the tumor periphery during the 30-minute initial observation period. From 5- to 10-fold more cells arrested in the tumor periphery than in the tumor center or in the neighboring fat-pad ( Figure 1E ).
Postmortem analysis of thin sections of tumors isolated 60 minutes after cell injection confirmed that CD34 + cells had selectively arrested in the tumor periphery rather than tumor center (Figure 1 , F and G; Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI24751DS1). Importantly, CD34 + cells were observed adhering to vessel walls within the lumens of CD31 + blood vessels, within vessel walls, and near the vessels within the tumor parenchyma ( Figure 1H ). These studies indicate that bone marrow-derived progenitor cells home selectively to the growing peripheral tumor vasculature and transmigrate into tumor tissue, suggesting that specific cell attachment and migration mechanisms may play a role in this homing response.
To determine whether CD34 -circulating cells (such as monocytes) also arrest within the peripheral vasculature of tumors, CD34 -mononuclear cells isolated from peripheral blood were labeled with a red fluorescent cell tracking dye and were injected into circulation of mice implanted with GFP + N202 breast carcinoma spheroids. Fluorescent cells were observed first rolling, then arresting in blood vessels at the tumor periphery ( Figure 2A ) but not at the tumor center (Figure 2A ), neighboring breast fatpad (Figure 2A ), or uninvolved skin (not shown). Within 15-20 minutes after injection, no further fluorescent cells were observed arresting in blood vessels. The arrested cells remained in the tumor periphery during the 30-minute initial observation period and for up to 3 days later (Figure 2A) . A significantly greater number of cells arrested in the tumor periphery than elsewhere ( Figure 2B ). Postmortem analysis of tissues confirmed that the human CD34 -cells were present only at the GFP + tumor periphery, just beyond the edge of the GFP + tumor ( Figure 2C ), even though CD31 + blood vessels were present both within the tumor and at the periphery of the tumor ( Figure 2C ). These studies show that CD34 -cells have the capacity to home to the tumor peripheral vasculature as well.
Integrin α 4 β 1 is expressed by CD34 + progenitor cells. To determine how circulating progenitor cells and other cells arrest in the peripheral tumor vasculature, we examined the roles of cell adhesion molecules in this process. Circulating cells such as lymphocytes utilize selectins to initiate contact with the blood vessel (rolling) and integrins α 4 or β 2 to arrest on the endothelium and extravasate from the circulation (22, 23) . Hematopoietic precursor cells also use integrin α 4 to adhere to bone marrow endothelia and to home back to the bone marrow from the circulation (24-26). To evaluate a role for specific adhesion proteins in progenitor cell homing, we examined the expression of integrins on circulating CD34 + cells. CD34 + cells were isolated to 98% purity from human PBMCs by 3 rounds of anti-CD34 magnetic bead affinity chromatography. CD34 + cells expressed significant levels of integrins α 4 (100%), α 5 β 1 (99%), α v β 3 (99%), and β 2 (68%) but little integrin α v β 5 ( Figure 3A) . The integrin α 4 subunit can combine with either the β 1 or the β 7 subunits, although the β 7 subunit has been detected only in small subsets of bone marrow-derived cells. We observed that the CD34 + cell population expresses high levels of the integrin β 1 subunit but did not express the integrin β 7 subunit (Supplemental Figure 2) . Thus, the integrin α 4 β 1 (VLA-4) is the primary α 4 integrin on CD34 + progenitor cells. Like CD34 + cells, CD34 -mononuclear cells also express high levels of the same integrins (Supplemental Figure 3 ). While endothelial cells express high levels of integrins α 5 β 1 , α v β 3 , and α v β 5 , they express low levels of integrin α 4 β 1 , no β 2 integrins, and no CD133. Thus, as CD34 + cells express CD133 and high levels of α 4 β 1 and β 2 integrin, but no α v β 5 , these cells are clearly not of endothelial origin ( Figure 3A) .
Integrin α Figure 3 , B and C). Together, these studies demonstrate that integrin α 4 β 1 selectively mediates the attachment of CD34 + progenitor cells to endothelia in vitro. As integrin α 4 β 1 is a receptor for connecting segment-1 (CS-1) fibronectin, an alternatively spliced form of cellular fibronectin (27) , and for VCAM, an immunoglobulin superfamily molecule expressed on endothelia in inflamed tissues (22) , these studies indicate that α 4 -VCAM or α 4 -fibronectin interactions can promote progenitor cell adhesion to endothelia. Indeed, proliferating endothelial cells express the α 4 β 1 ligands cellular fibronectin (27) and VCAM ( Figure 3D ). CD34 + cells also adhere to the CS-1 domain of cellular fibronectin in an integrin α 4 β 1 -dependent manner ( Figure 3E ). By comparison, CD34 -mononuclear cells also express high levels of integrin α 4 β 1 and adhere to endothelia and CS-1 fibronectin in an α 4 β 1 -dependent manner (Supplemental Figure 3) .
Integrin α Human CD34 + progenitor cells have been previously shown to differentiate into endothelial cells in vivo and to thereby participate in blood vessel formation in vivo (1-3). We also found that a subset of CD34 + progenitor cells injected into animals bearing subcutaneous tumors differentiated into endothelial cells that helped to form blood vessel structures (Supplemental Figure 5) . Importantly, antagonists of human integrin α 4 β 1 but not antagonists of integrin α v β 3 inhibited CD34 + progenitor cell differentiation into endothelial cells (Supplemental Figure 5 ). These human CD34 + cells in CD31 + blood vessels expressed the proliferating cell antigen Ki67, indicating their proliferative status (Supplemental Figure 5 ). These studies suggest that integrin α 4 β 1 regulates CD34 + progenitor cell roles in blood vessel formation by promoting progenitor cell homing to tissues.
Integrin α ously shown to participate in blood vessel formation in vivo by differentiating into endothelial cells (3, 28) . We compared the integrin expression and adhesion profiles of mouse bone marrow-derived lineage-positive (Lin + ) and lineage-negative (Lin -) progenitor cell populations and Lin -Sca1 + stem cell-enriched populations (29) . Like human bone marrow-derived cells, murine Lin + , Lin -, and Lin -Sca1 + cells expressed high levels of integrins α 4 β 1 , α 5 β 1 , α v , and β 2 ( Figure 5A ). Each of these cell populations adhered to cultured ECs exclusively in an α 4 β 1 -dependent manner, as only anti-integrin α 4 β 1 antibodies and rsVCAM, but not other integrin inhibitors, were able to suppress cell adhesion to endothelia ( Figure 5, B-E) .
To evaluate the ability of murine progenitor cells to home to tumor blood vessels, we injected EGFP + Lin -progenitor cells into animals with LLC tumors in the presence of saline, anti-α 4 β 1 , anti-VCAM, rsVCAM, or control IgG for 12 hours. We found that Lincells homed to tumors and that this homing was inhibited by anti-α 4 β 1 , rsVCAM, and anti-VCAM ( Figure 6, A and B) . These results indicate that Lin -progenitor cells home to tumor neovasculature in an integrin α 4 β 1 - and VCAM-dependent manner.
To evaluate the ability of murine progenitor cells to participate in blood vessel formation, we injected EGFP + Lin -progenitor cells and EGFP + Lin + cells into animals with LLC tumors. After 5 days in vivo, EGFP + Lin -cells had homed to tumors, and some cells had formed EGFP + blood vessels, primarily at the tumor periphery ( Figure 6C and Supplemental Figure 6 ). Importantly, EGFP + Lin + bone marrow-derived cells similarly injected homed to tumors but did not contribute to vessel formation although these cells homed to tumors and were found within the tumor tissue ( Figure 6C ). We next injected murine EGFP + Lin -progenitor cells into animals with LLC tumors in the presence or absence of anti-α 4 β 1 or isotype-matched anti-integrin β 2 antibodies. In contrast to control-treated animals, few EGFP + Lin -cells ( We also injected murine EGFP + Lin + cells into animals with LLC tumors in the presence or absence of anti-α 4 β 1 or isotypematched anti-integrin antibodies. Numerous EGFP + Lin + cells were found in the tumor periphery of control-treated mice, but few EGFP + Lin + cells were observed in tumors of anti-α 4 β 1 -treated mice (Figure 6 , D and G). Our studies show that integrin α 4 β 1 promotes homing of circulating progenitor cells and other bone marrow-derived mononuclear cells to tumor vessels. These studies also indicate that inhibition of progenitor cell homing to the tumor vasculature prevents their participation in neovascularization by differentiation into endothelial cells. Our studies thus indicate that integrin α 4 β 1 mediates progenitor cell attachment to the tumor endothelium, extravasation, and subsequent participation in blood vessel formation.
Integrin α 4 β 1 ligands are expressed primarily at the tumor periphery. To determine whether ligands for the integrin α 4 β 1 are expressed by the tumor neovasculature, we examined tissues undergoing neovascularization for expression of the α 4 β 1 ligands VCAM and cellular fibronectin. Both VCAM and fibronectin are expressed in breast tumor endothelium, which is identified by anti-CD31 immunostaining ( Figure 7 ). In fact, both ligands are expressed at much greater levels in the tumor periphery than in the tumor center ( Figure 7 ). These ligands are rarely expressed by normal endothelia, although fibronectin was occasionally observed around large vessels in normal tissues (Figure 7 ). These results demonstrate that the α 4 β 1 ligands VCAM and fibronectin are expressed in the tumor periphery where they appear to promote the adhesion of α 4 α 4 β 1 plays a role in the natural homing of progenitor cells from bone marrow to neovasculature, mice were transplanted with bone marrow from Tie2LacZ mice. In Tie2LacZ mice, endothelial cells express β-galactosidase under the control of the promoter of the endothelial protein Tie2 (Supplemental Figures 7 and 8) . Large vessels as well as small, single-celled vessels stain positively for β-galactosidase expression by both colorimetric (Supplemental Figure 7) and fluorescent immunostaining (Supplemental Figure 8) methods. In mice transplanted with Tie2LacZ bone marrow, bone marrow-derived endothelial cells expressed β-galactosidase under the control of the promoter of the endothelial protein Tie2 (1, 2) .
Angiogenesis was stimulated in the Tie2LacZ bone marrowtransplanted mice by implantation of growth factor-reduced Matrigel saturated with VEGF or bFGF. These growth factors induced an angiogenic response as well as the homing of β-galactosidase-positive (βGal + ) cells (Figure 8, A and B) . Many of these cells formed small vessels composed of single cells, which could be detected by microscopy at high magnification ( Figure 8B ). Treatment of mice with anti-α 4 β 1 but not anti-integrin β 2 function-blocking antibodies blocked the incorporation of βGal + cells into the Matrigel (Figure 8, A-C) . Immunological detection of β-galactosidase and CD31 expression demonstrated that many βGal + cells incorporated into CD31 + blood vessels ( Figure 8D and Supplemental Figure 9 ). Importantly, antagonists of α 4 β 1 but not of β 2 integrin blocked this incorporation into the vasculature (Figure 8 , D-E) and suppressed angiogenesis ( Figure 8F ).
Our studies indicate that integrin α 4 β 1 , but not other integrins, potentiates progenitor/stem cell trafficking to tumors and remodeling tissues undergoing neovascularization. This integrin promotes progenitor cell attachment to the neovascular endothelium, endothelial transmigration, and new blood vessel formation in remodeling tissues. 
Discussion
Our studies demonstrate that integrin α 4 β 1 -VCAM/fibronectin interactions promote the homing of progenitor cells and other circulating mononuclear cells to vascular endothelia during neovascularization and tissue remodeling. Our work identifies a key mechanism regulating progenitor cell homing to target tissues. This is a significant advance in our understanding of how progenitor and/or stem cells find their way to a specific tissue microenvironment. Once localized in a tissue, progenitor cells may promote tissue repair by differentiating into a number of cell types, including endothelial cells, smooth muscle cells, muscle cells, and neuronal cells (1-13) . The use of CD34 + bone marrow-derived progenitor cells is thus under consideration for the therapy of diseased or damaged tissues. Development of methods to enhance homing of progenitors to target tissues could facilitate tissue repair. Our studies suggest that manipulation of the expression and/or function of α 4 β 1 and its ligands may improve therapeutic bone marrow transplantation or be used to inhibit progenitor/stem cell contributions to pathological processes such as tumor angiogenesis.
Integrin α 4 β 1 -VCAM interactions promote several key heterotypic cell adhesion events in vivo. During normal embryonic development, this integrin promotes fusion of the chorion with the allantois and fusion of endocardium with myocardium (30, 31) . Integrin α 4 β 1 and fibronectin or VCAM interactions are also critical for T cell and natural killer cell trafficking during inflammation (22, 23) and cancer (32) , for adhesion of immune cell precursors to bone marrow endothelia, and for circulating cell homing to the bone marrow (24, 25) . More recently, we showed that this integrin also promotes intercellular adhesion of endothelial cells and pericytes during angiogenesis, thereby promoting subsequent blood vessel formation (21) . Although previous studies showed that integrin α 4 β 1 antibodies mobilize progenitor cell release from bone marrow and block progenitor cell return to bone marrow (24, 25) , our studies now show that these antibodies also block, rather than promote cell homing to neovascular tissue. The studies presented here indicate yet another role for this integrin-ligand pair, the homing of progenitor cells and other circulating bone marrowderived cells to proliferating or activated endothelia.
In our studies of progenitor cell homing to tumors, we observed that cells traveled throughout all the vessels of the tumor but only attached within the tumor vessels at the periphery of the tumor. We identified biochemical differences, expression of VCAM and fibronectin, between the peripheral and central vasculature. These differences were not attributable to central tumor necrosis, as the tumors observed were small with no evidence of necrosis. Our studies include dynamic analyses of homing as the in vivo studies successively analyzed the movement of adoptively transferred cells within a time frame of minutes (intravital microscopy), hours (N202 and LLC tumors with CD34 + cells and Lin -cells), and days (CD34 + and Lin -cell transfer). Use of intravital microscopy in studies of CD34 + cells could not distinguish cells adhering to the vascular wall from cells just beneath the endothelium. However, immunohistochemistry of thin cryosections shows that cells can be found both within vessels, adhering to the vessel wall, and inside tissues. Thus, our studies show that cells first attach to the vessel wall, then migrate into tissues. Longer term, 5-day studies show that Lin -cells form blood vessels while others remain as single cells within the tissues. In contrast, Lin + cells never make vessels but do home to tumors and extravasate into tissues.
Our studies with human CD34 + cells and selective anti-human integrin antibodies demonstrated that human integrin α 4 β 1 on CD34 + cells promotes homing of progenitor cells to murine neovessels. Our studies with murine Lin -cells and anti-murine α 4 β 1 antibodies reproduced these findings. The in vitro and in vivo human and murine studies combined clearly demonstrate that integrin α 4 β 1 on circulating progenitor cells promotes homing to neovessels. In our studies, only antagonists of integrin α 4 and β 1 integrins blocked cell adhesion to proliferating endothelia in vitro or in vivo. Our studies utilizing antagonists of integrin α v β 3 , α v β 5 , α 5 β 1 , and β 2 integrins demonstrated that these other integrins are unlikely to play major roles in homing of circulating cells to tumors. Recent studies have suggested that β 2 integrins, rather than integrin α 4 β 1 , promote endothelial progenitor cell homing to neovessels (33) . In these studies, a population of adherent PBMCs cultured in endothelial growth medium were characterized as endothelial progenitor cells and served as the basis for adoptive transfer studies. We and others have found that this population of cells are derived from monocytes, as they express myelocytic markers, including CD14, CD68, and α M β 2 , and fail to express CD34 or CD133, 2 key markers of progenitor cells (34) . Our studies suggest that integrin β 2 does not contribute to progenitor cell homing to tumors. However, as both of these integrins have been shown to promote lymphocyte trafficking, it remains possible that both receptors modulate progenitor cell trafficking in distinct clinical settings.
Our studies showed that bone marrow-derived progenitor cells home to tumor vasculature and can differentiate into endothelia, thereby participating in angiogenesis. We showed that only Linand not Lin + cells formed blood vessels. Several previous studies have shown that murine Lin -and human CD34 + bone marrowderived progenitor cell populations contain endothelial progenitor cells (1-4, 15, 16, 28) . Although some controversy has arisen over the existence of bone marrow-derived endothelial precursors, recent studies have identified a common bone marrow-derived precursor for endothelial cell and hematopoietic cell lineages. For example, a common Lin -Sca1 + stem cell (the hemangioblast) for endothelial cell and hematopoietic cell lineages was isolated from adult murine bone marrow using single cell transplantation analysis (28) , demonstrating the clear presence of common endothelia/hematopoietical progenitor cells among bone marrow-derived cell populations. Additionally, other studies have shown that endothelial and hematopoietic cells arise during embryogenesis from a common precursor cell, the hemangioblast (35, 36) . Although recent studies demonstrated in a variety of animal models that only about 15-20% of tumor vessels arise from the bone marrow (16) , other studies indicated that in the absence of sprouting angiogenesis, bone marrow-derived angiogenesis alone could promote tumor growth (15) . Importantly, recently published work demonstrated that sex-mismatched human bone marrow transplant recipients who later develop cancer exhibit bone marrow-derived endothelial cells within tumor vessels (37) . Furthermore, adoptively transferred CD34 + progenitor cells promoted angiogenesis and improved heart function in animal studies (1) (2) (3) . Our studies thus indicate that integrin α 4 β 1 mediates progenitor cell attachment to the tumor endothelium, extravasation, and, therefore, subsequent participation in blood vessel formation. As Lin -Sca1 + stem cells give rise to endothelial and hematopoietic cell lineages (28) and adhere to endothelia in an α 4 β 1 -dependent manner, our studies suggest that these bone marrow-derived stem cells also home to the tumor vasculature in an α 4 β 1 -dependent manner.
We found that both VCAM and cellular fibronectin are expressed at the tumor periphery, the location to which CD34 + cells home. Fibronectin is typically localized on the abluminal side of the blood vessel while VCAM is localized on the luminal side. It is possible that the fibronectin is accessible to circulating cells, as tumor neovasculature is characteristically leaky. Tumor-derived VEGF inhibits VE-cadherin-mediated intercellular adhesion of endothelial cells and allows circulating cells, including platelets, to contact the basement membrane of VEGF-stimulated vessels (38) . It is also possible that circulating cells recognize VCAM on the luminal side of endothelia and use cellular fibronectin for migration beneath endothelia. As VCAM is also expressed on the endothelia of vessels in inflamed or ischemic tissues, it is likely that integrin α 4 β 1 promotes the homing of circulating progenitor cells and other bone marrow-derived mononuclear circulating cells not only to tumor tissues but also to inflamed and ischemic tissues.
Antagonists of the bone marrow-derived component of angiogenesis could be useful in combination with inhibitors of sprouting angiogenesis to most thoroughly suppress tumor angiogenesis. Additionally, our studies suggest that manipulation of the expression and function of α 4 β 1 and its ligands may improve therapeutic bone marrow transplantation or be used to inhibit progenitor/stem cell contributions to pathological processes such as tumor angiogenesis. 
Methods
Progenitor cell isolation
PBMCs (3.7 × 10 9 ) were purified by gradient centrifugation from human blood obtained from the San Diego Blood Bank. From these, 3 × 10 6 CD34 + cells at 98% purity (as determined by FACS analysis for CD34 expression) were isolated by positive selection by 3 rounds of immune selection for human CD34 (Miltenyi Biotech).
All animal studies were approved by the Institutional Animal Care and Use Committees of UCSD, The Scripps Research Institute, and Sidney Kimmel Cancer Center. EGFP + bone marrow-derived mononuclear cells (3 × 10 8 ) were purified by gradient centrifugation from the femurs and tibias of 6 ACTB-EGFP mice. Lin -cells (4.8 × 10 6 ) were isolated from bone marrowderived mononuclear cells by 2 rounds of negative selection for a panel of lineage markers (CD5, B220, CD11b, Gr-1, 7-4, and Ter119; Miltenyi 
